Natixis Advisors LLC Sells 91,947 Shares of Haleon PLC Sponsored ADR $HLN

Natixis Advisors LLC cut its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 4.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,888,308 shares of the company’s stock after selling 91,947 shares during the quarter. Natixis Advisors LLC’s holdings in Haleon were worth $16,938,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. Grantham Mayo Van Otterloo & Co. LLC grew its position in Haleon by 13.2% during the third quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 888,839 shares of the company’s stock valued at $7,973,000 after buying an additional 103,601 shares during the period. Blair William & Co. IL boosted its stake in Haleon by 5.8% in the third quarter. Blair William & Co. IL now owns 47,834 shares of the company’s stock valued at $429,000 after acquiring an additional 2,614 shares during the last quarter. First Trust Advisors LP boosted its stake in Haleon by 22.3% in the third quarter. First Trust Advisors LP now owns 182,008 shares of the company’s stock valued at $1,633,000 after acquiring an additional 33,175 shares during the last quarter. Barclays PLC bought a new position in shares of Haleon during the 3rd quarter valued at approximately $2,422,000. Finally, First Eagle Investment Management LLC grew its position in shares of Haleon by 9.8% during the 3rd quarter. First Eagle Investment Management LLC now owns 3,056,951 shares of the company’s stock valued at $27,421,000 after acquiring an additional 273,044 shares during the period. 6.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft cut shares of Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. HSBC upgraded Haleon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Price Performance

HLN stock opened at $10.00 on Thursday. The firm has a 50 day moving average of $10.50 and a 200-day moving average of $9.85. The firm has a market capitalization of $44.51 billion, a P/E ratio of 25.63 and a beta of 0.18. Haleon PLC Sponsored ADR has a 12 month low of $8.71 and a 12 month high of $11.42. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47.

Haleon Dividend Announcement

The company also recently declared a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be issued a $0.1307 dividend. This represents a yield of 251.0%. The ex-dividend date of this dividend is Friday, April 10th. Haleon’s dividend payout ratio (DPR) is presently 61.54%.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.